CRIS · Curis, Inc.
AI read · Neutral
The AI's read
The trial work gives Curis a possible path toward treatment applications. Earlier results showed responses in some patients with PCNSL, and regulators said the ongoing study could support applications for quicker approval. Those results were reported in July, not in this update. Curis also reported a larger loss over nine months and no sales for the quarter. Recent funding is expected to cover costs into 2027, so the positives and negatives leave the outlook mixed.